CRL reported Q1 in line with its cautious guidance, showing a sequential margin improvement and a step-up in EPS for Q2. Management reaffirmed full-year guidance, highlighting a strong margin expansion in the second half driven by acquisitions, divestitures, and cost cuts. The commentary on proposal volumes and client discussions points to a gradual demand recovery. Q1 EPS was $2.06, with free cash flow negative at -$15 million due to bonus payouts.
CRL reported Q1 in line with its cautious guidance, showing a sequential margin improvement and a step-up in EPS for Q2. Management reaffirmed full-year guidance, highlighting a strong margin expansion in the second half driven by acquisitions, divestitures, and cost cuts. The commentary on proposal volumes and client discussions points to a gradual demand recovery. Q1 EPS was $2.06, with free cash flow negative at -$15 million due to bonus payouts.
Management highlighted improving demand indicators (proposals up high single digits, biotech funding improving) but also noted continued headwinds like FX and early-stage biotech sluggishness, maintaining a cautious outlook.
Reported gross margin was 28.05%, reinforcing the quarter's better-than-guided profitability.
Guidance · revenue to -4.75%
Proposals up high single digits year-over-year in both pharma and biotech segments. Management highlighted improving demand indicators (proposals up high single digits, biotech funding improving) but also noted continued headwinds like FX and early-stage biotech sluggishness…
AI is viewed as a positive, long-term driver for preclinical testing demand. Management is optimistic that AI-assisted drug discovery will lead to more programs entering the pipeline, but notes it is early days. AI is also being invested in for internal efficiency and to reduce animal usage, and NAMs are being integrated into the business as an evolution, not a revolution.
Proposals up high single digits year-over-year in both pharma and biotech segments. Management highlighted improving demand indicators (proposals up high single digits, biotech funding improving) but also noted continued headwinds like FX and early-stage biotech sluggishness, maintaining a cautious outlook.
CapEx declined modestly in Q1 to $56 million, approximately 5.6% of revenue. Management did not provide forward-looking capex guidance but emphasized disciplined capital allocation with a focus on M&A, buybacks, and organic investments.
Management highlighted improving demand indicators (proposals up high single digits, biotech funding improving) but also noted continued headwinds like FX and early-stage biotech sluggishness, maintaining a cautious outlook.
“The external customer that you're referring to is actually from our Mauritius farms, and when we bought the Mauritius farm, we bought the external relationship with the supply. Ultimately, the goal is to use the animals on safety assessmen…”
“What we're seeing currently is quite an acceleration of when clients come in on a proposal and then book and place the study... we sometimes see literally from a proposal to getting revenue within the same quarter.”
“What I can tell you is that AI assisted drug discovery companies generally work on a lot of different programs rather than one program at a time.”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| EPS | FY2026 | $10.80–$11.30 | $11.05 | MAINTAINED |
| Free cash flow | FY2026 | $375M–$400M | $387.5M | MAINTAINED |
| Revenue | FY2026 | -5.5%–-4% | -4.75% | LOWERED |
The NHP supply contract from the Mauritius farm with an external customer will be wound down over the next few quarters, freeing up animal supply for internal studies and improving vertical integration. — This will shift supply away from competitors and independent CROs, potentially reducing their ability to source NHPs competitively, giving CRL a cost and supply advantage.
“The external customer that you're referring to is actually from our Mauritius farms, and when we bought the Mauritius farm, we bought the external relationship with the supply. Ultimately, the goal is to use the animals on safety”
Okay, perfect. And then following up, so with how much of the NHP P-supply from Novoprim and KF is still obligated to external customers, and then when does that fully become available to Charles River? Thank you.
Yeah, I can talk about that. So the external customer that you're referring to is actually from our Mauritius farms, and When we bought the Mauritius farm, we bought the external relationship with the supply. Ultimately, the goal is to use the animals on safety assessment studies and moving them over. And that will kind of be a transition over the next few years. And as you can see, you'll probably see that we already have more and more animals on our safety study. And then that will kind of end over the next few quarters.
AI-assisted drug discovery companies typically work on many more programs simultaneously than traditional biotechs, which could increase the volume of preclinical work that gets outsourced to CRL. — As AI-native drug developers scale, they are more likely to outsource their 'wet lab' work, creating a new and potentially larger pipeline of customers for contract research organizations.
We're three quarters in a row. Okay. Maybe another question. unrelated question here on AI. Birgit, it sounded like, you know, your comments, your prepared remarks, it sounded like you feel pretty comfortable with this idea that AI investments in drug discovery are going to lead to more preclinical testing longer term. Are you seeing that play out at all yet, or is that more something that, you know, we really probably don't see until, you know, we get a couple years into the future here?
Yeah, thanks for that question. So, I'm actually personally very excited about AI and what it will do for the In particular, so right now the sample set of AI discovered or assisted, I should say, drug programs is very, very small. So it's hard to make a real conclusion from that. What I can tell you is that AI assisted drug discovery companies generally work on a lot of different programs rather than one program at a time. And as we're working with most of them, all of them, on their programs as their web lab, I'm optimistic that this trend will show itself and that we will see more programs coming through from AI. It also should still need to be seen. lower the cost of early discovery. And with that, there's more money for reinvestment. But again, it's very early days. There's so few programs in the pipeline that are AI-assisted. But just theoretically, hypothetically, we know that AI will have a nice impact on that.
Biotech clients are moving from proposal to booking to revenue faster than in the past, compressing the typically 1-2 quarter cycle, which improves backlog quality and reduces cancellation risk.